Finding 1224299 (2025-005)

Material Weakness Repeat Finding
Requirement
P
Questioned Costs
-
Year
2025
Accepted
2026-07-21
Audit: 407580
Organization: HEALTHX PARTNERS INCORPORATED (DC)
Auditor: BDO

AI Summary

  • Core Issue: HealthXP identified three instances of fraud affecting federally funded programs, all reported to the U.S. Office of the Inspector General.
  • Impacted Requirements: Compliance with §200.516(a) requires reporting known or suspected fraud; no financial loss to the U.S. Government occurred as amounts were recovered.
  • Recommended Follow-Up: Continue utilizing the global internal audit team and fraud reporting hotline to strengthen fraud detection and mitigation efforts.

Finding Text

Allegations of Fraud Identification of the Federal Programs: See Schedule of Findings and Questioned Costs for table. Criteria: §200.516(a) Audit findings requires known or suspected fraud be reported by the auditor. Condition: During 2025, HealthXP identified three instances of fraud through its internal reporting mechanisms that impacted the Organization’s federally funded programs. These incidents have been reported to the appropriate U.S. Office of the Inspector General. See details below. • In Mozambique, a subrecipient confirmed fraudulent expenditures of $359.66 and questioned costs of $186.00. This resulted from a falsified contract for office rent and misrouted utility invoices. The amount was remitted by the subrecipient, as such, there was no loss to the U.S. Government. Centers for Disease Control award NU2GGH002369. • In Tanzania, a subrecipient’s program officer circumvented controls for the entity’s payment system, forged authorization documents and redirected payments totaling $3,366. Duplicate payments of $240 were also identified. Amounts were fully recovered from the subrecipient. There was no financial loss to the U.S. Government. USAID contract #72062122C00001. • In Cote d’Ivoire, allegations regarding falsified hotel receipts of per diem was substantiated. The impact to award 72062421CA00003 was $129 and was subsequently fully recovered. There was no financial loss to the U.S. Government. HealthXP has ongoing investigations involving Federal funding pending in multiple countries for which the facts and circumstances and full effect of the fraud investigations have not been determined. Where investigations are still pending and conclusions of the matters identified through whistleblower or other communications have not been reached, HealthXP has reported such matters to the appropriate U.S. agency. Questioned Costs: There are no questioned costs as the questioned amounts have been, or are in the process of, being reimbursed to the respective Federal agency. The questioned amounts are not included or presented in the Schedule. Context: These conditions were identified through HealthXP’s internal review and audit processes and were reported to us during our internal control assessment for the year ended December 31, 2025. Cause: Individuals intentionally circumvented HealthXP or related subrecipient’s established internal controls. Effect: These conditions could result in unallowable expenses being charged to U.S. Government awards if controls in place had not identified the conditions. Repeat Finding: The specific items identified above were not reported in the prior year; however, findings related to fraud were included in the prior year report of PSI for the prior year as findings 2024-004 in the December 31, 2024 schedule of findings and questioned costs. Recommendation: Because of the international environment in which HealthXP entities operate, the potential for fraud is heightened. Given this, we recommend management continue to utilize its global internal audit team and fraud reporting hotline, as well as other policies and procedures around fraud identification to mitigate the fraud risk. Views of Responsible Officials: HealthXP management agrees with the finding and recommendations set forth within and will proactively report and investigate allegations of fraud and to raise awareness of the actions to be taken when there is a suspicion of fraud. Refer to management’s correction action plan for additional information.

Corrective Action Plan

Allegations of Fraud Contact: Katie Queen Dossinger Title: Chief Operating Officer Phone Number: 202-785-0072 Estimated Completion Date: Ongoing Corrective Action HealthXP manages fraud risk through a combination of preventative, detective, and monitoring controls, and reinforces its expectations regarding ethical behavior through training and communications. HealthXP proactively reports and investigates allegations of fraud and raises awareness of the actions to be taken when fraud is suspected. The HealthXP Global Internal Audit and Investigations team shares lessons learned from its work. Given the challenging operating environments in which HealthXP implements its programs, fraud remains an ongoing risk that HealthXP actively monitors, investigates, and mitigates.

Categories

Subrecipient Monitoring Allowable Costs / Cost Principles Reporting Internal Control / Segregation of Duties

Other Findings in this Audit

  • 1224236 2025-001
    Material Weakness Repeat
  • 1224237 2025-001
    Material Weakness Repeat
  • 1224238 2025-001
    Material Weakness Repeat
  • 1224239 2025-001
    Material Weakness Repeat
  • 1224240 2025-001
    Material Weakness Repeat
  • 1224241 2025-001
    Material Weakness Repeat
  • 1224242 2025-001
    Material Weakness Repeat
  • 1224243 2025-001
    Material Weakness Repeat
  • 1224244 2025-001
    Material Weakness Repeat
  • 1224245 2025-001
    Material Weakness Repeat
  • 1224246 2025-005
    Material Weakness Repeat
  • 1224247 2025-001
    Material Weakness Repeat
  • 1224248 2025-001
    Material Weakness Repeat
  • 1224249 2025-001
    Material Weakness Repeat
  • 1224250 2025-001
    Material Weakness Repeat
  • 1224251 2025-001
    Material Weakness Repeat
  • 1224252 2025-001
    Material Weakness Repeat
  • 1224253 2025-001
    Material Weakness Repeat
  • 1224254 2025-001
    Material Weakness Repeat
  • 1224255 2025-001
    Material Weakness Repeat
  • 1224256 2025-001
    Material Weakness Repeat
  • 1224257 2025-001
    Material Weakness Repeat
  • 1224258 2025-001
    Material Weakness Repeat
  • 1224259 2025-001
    Material Weakness Repeat
  • 1224260 2025-001
    Material Weakness Repeat
  • 1224261 2025-001
    Material Weakness Repeat
  • 1224262 2025-001
    Material Weakness Repeat
  • 1224263 2025-001
    Material Weakness Repeat
  • 1224264 2025-001
    Material Weakness Repeat
  • 1224265 2025-001
    Material Weakness Repeat
  • 1224266 2025-001
    Material Weakness Repeat
  • 1224267 2025-001
    Material Weakness Repeat
  • 1224268 2025-001
    Material Weakness Repeat
  • 1224269 2025-001
    Material Weakness Repeat
  • 1224270 2025-001
    Material Weakness Repeat
  • 1224271 2025-001
    Material Weakness Repeat
  • 1224272 2025-001
    Material Weakness Repeat
  • 1224273 2025-004
    Material Weakness Repeat
  • 1224274 2025-001
    Material Weakness Repeat
  • 1224275 2025-001
    Material Weakness Repeat
  • 1224276 2025-001
    Material Weakness Repeat
  • 1224277 2025-001
    Material Weakness Repeat
  • 1224278 2025-001
    Material Weakness Repeat
  • 1224279 2025-001
    Material Weakness Repeat
  • 1224280 2025-001
    Material Weakness Repeat
  • 1224281 2025-001
    Material Weakness Repeat
  • 1224282 2025-001
    Material Weakness Repeat
  • 1224283 2025-001
    Material Weakness Repeat
  • 1224284 2025-001
    Material Weakness Repeat
  • 1224285 2025-001
    Material Weakness Repeat
  • 1224286 2025-001
    Material Weakness Repeat
  • 1224287 2025-001
    Material Weakness Repeat
  • 1224288 2025-001
    Material Weakness Repeat
  • 1224289 2025-004
    Material Weakness Repeat
  • 1224290 2025-005
    Material Weakness Repeat
  • 1224291 2025-003
    Material Weakness Repeat
  • 1224292 2025-002
    Material Weakness Repeat
  • 1224293 2025-003
    Material Weakness Repeat
  • 1224294 2025-003
    Material Weakness Repeat
  • 1224295 2025-003
    Material Weakness Repeat
  • 1224296 2025-003
    Material Weakness Repeat
  • 1224297 2025-003
    Material Weakness Repeat
  • 1224298 2025-003
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
98.U00 USAID/Tanzania's Client-Centered Health Program - HIV and Tuberculosis Northern (C3HP-NIV&TB Northern) $15.41M
98.U00 Global Health Supply Chain (GSHC) - Procurement and Supply Management (PSM) $3.18M
12.350 DEPARTMENT OF DEFENSE HIV/AIDS PREVENTION PROGRAM $2.64M
98.U00 Donated Commodities $2.17M
98.U00 Southern Africa's Attain & Sustain 95-95-95, Present New Infections and Reach All Populations for Epidemic Control (ASPIRE) $1.03M
93.067 GLOBAL AIDS $1.01M
98.001 USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS $894,682
12.420 MILITARY MEDICAL RESEARCH AND DEVELOPMENT $203,175
98.U00 PMI Prevention of Malaria Through Vector Control $190,245
98.U00 USAID Western Kenya Sanitation (WKSP) $146,407
98.U00 Ethiopia Urban Water, Sanitation and Hygiene (WASH) Activity $123,146
98.U00 USAID West Africa Municipal Wash (MuniWASH) $66,273
98.U00 USAID WASH Services $60,267
98.U00 WCA_USAID_Transform IDIQ $1,285